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Abstract
Primary Liver Cancer (PLC) is the leading cause of death by cancer among males in Thailand and the 3
rd among females.
Most cases are hepatocellular carcinoma (HCC) but cholangiocarcinomas represent between 4 and 80% of liver cancers
depending upon geographic area. Most HCC are associated with chronic infection by Hepatitis B Virus while a GRT
mutation at codon 249 of the TP53 gene, R249S, specific for exposure to aflatoxin, is detected in tumors for up to 30% of
cases. We have used Short Oligonucleotide Mass Analysis (SOMA) to quantify free circulating R249S-mutated DNA in plasma
using blood specimens collected in a hospital case:control study. Plasma R249S-mutated DNA was detectable at low
concentrations ($67 copies/mL) in 53 to 64% of patients with primary liver cancer or chronic liver disease and in 19% of
controls. 44% of patients with HCC and no evidence of cirrhosis had plasma concentrations of R249S-mutated DNA $150
copies/mL, compared to 21% in patients with both HCC and cirrhosis, 22% in patients with cholangiocarcinoma, 12% in
patients with non-cancer chronic liver disease and 3% of subjects in the reference group. Thus, plasma concentrations of
R249S-mutated DNA $150 copies/mL tended to be more common in patients with HCC developing without pre-existing
cirrhosis (p=0.027). Overall, these results support the preferential occurrence of R249S-mutated DNA in HCC developing in
the absence of cirrhosis in a context of HBV chronic infection.
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Introduction
Liver cancer accounts for approximately 6% of all new cancer
cases diagnosed worldwide; it is the fifth most common cancer in
men and the eighth most common in females worldwide [1,2].
The majority of primary liver cancers in adults are hepatocellular
carcinoma (HCC; 90%) whereas cholangiocarcinomas (CC)
account for about 9% of the cases, with peaks in incidence in
parts of South-East Asia. Approximately 80% of HCCs and the
resulting deaths occur in low and middle income countries of
Eastern Asia, Sub-Saharan Africa and South America, where high
incidences of Hepatitis B Virus (HBV) and/or Hepatitis C Virus
(HCV) are endemic and where aflatoxin-contaminated staple
foods are consumed [3]. CC develops in intra-hepatic billiary
epithelial cells and is caused by the chronic infection of billiary
ducts by liver flukes Opisthorchis viverrini and Clornorchis Sinesis. These
liver flukes are endemic mainly in Eastern Asia, notably in
Thailand, Laos, Vietnam and South-Eastern China [4]. According
to a recent evaluation of the carcinogenic risk to humans by the
International Agency for Research on Cancer Monographs, there
is only limited evidence for association chronic HBV/HCV with
risk of CC and no evidence for association with aflatoxin exposure
[5,6].
In Thailand, liver cancer is the leading cause of death from
cancer among men (age-standardized incidence rates, world
standard, ASR=35.1) and the third leading cause in women
(ASR=16.6) [1]. The geographical distribution of cholangiocar-
cinoma matches the prevalence of chronic infection by O. viverrini,
which is endemic in the north-east and rare in southern Thailand.
In males, the age-standardized incidence rates (ASR, world
standard) for HCC and CC, respectively, are 11.6 and 7.2 for
Chiang Mai, 11.0 and 10.4 for Lampang, 12.5 and 67.5 for Khon
Kaen, 8.3 and 2.2 for Bangkok and 5.9 and 0.4 for Songkhla [7].
In Thailand, nationwide infant vaccination against HBV began in
1992 [8,9].
Aflatoxin exposure is a major risk factor for HCC in particular
in regions where exposure to HBV is endemic. Aflatoxins are
fungal toxins produced by Aspergillus flavus and Aspergillus parasiticus,
which contaminate staple foods including groundnuts. Storage of
crops in hot humid conditions can promote growth of the
aflatoxin-producing fungi and results in increased accumulation of
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metabolized by P450 enzymes in the liver to generate an epoxide
which is highly reactive with DNA, forming adducts at N7 position
of Guanine. Lack of repair of this lesion may lead to permanent
DNA mutations, preferentially G to T transversions. A hotspot for
mutation by AFB1 has been identified at codon 249 in the TP53
suppressor gene (AGG to AGT, Arginine to Serine, R249S).
Recent evidence confirms that this position is a preferential site for
AFB1 adduct formation [12]. There is a remarkable ecological
concordance between AFB1 exposure, chronic HBV infection and
presence of R249S in HCC [13,14]. However, how the mutant
protein p.R249S contributes to hepatocarcinogenesis and co-
operates with HBV in this process is still a matter of debate.
In Thailand, the main dietary sources of exposure to AFB1 are
maize and groundnuts (peanuts). Individual exposure to AFB1 has
been estimated to vary between 53 and 73 ng/kg/day, although
this figure is likely to differ widely among geographic areas and
ecological zones [11]. A recent estimate of the risk of HCC
attributable to aflatoxin for Thailand has provided figures of 0.53–
0.73 and 15.9–21.9/10
5 person years, in HBsAg-negative and
positive subjects, respectively [11]. In a recent study on a small
group of surgically resected HCC patients at the National Cancer
Institute, Bangkok, we reported R249S mutation in 7/26 (27%)
cases, suggesting that the contribution of AFB1 to the burden of
HCC in Thailand is far from negligible [15]. However, an earlier
epidemiological study in Thailand using a albumin-adduct bio-
marker to assess aflatoxin exposure, failed to identify an aflatoxin-
associated risk for HCC [16].
In previous studies, we and others have shown that circulating
free DNA (CFDNA) from plasma is a suitable surrogate source of
liver-derived DNA for detection of R249S mutations. Overall
levels of CFDNA are higher in patients with liver cancer than
controls (for review see [17]). In the Gambia and in the Qidong
area of People’s Republic of China, two regions of high HBV
prevalence and widespread AFB1 exposure, high plasma concen-
trations of R249S-mutated DNA were found to be strongly
associated with HCC [18,19]. In the Gambia, the use of a highly
sensitive mass spectrometric technique (Short Oligonucleotide
Mass Analysis, SOMA) has allowed detection of low levels R249S-
mutated DNA in the plasma of asymptomatic HBV carriers,
suggested to occur as a result of ongoing AFB1 exposure [20]. In
Thailand, a previous study comparing HCC cases and controls has
reported the SOMA detection of R249S-mutated DNA in 9/34
HCC cases (26%) and in 10/68 (14.7%) controls [21]. In this
study, we have used plasma collected in a case-referent design at
National Cancer Institute, Bangkok, to evaluate the association of
R249S-mutated DNA plasma concentrations with the occurrence
of HCC, CC or chronic liver disease. Our results suggest
a preferential association between R249S and HCC developing
in the absence of documented previous history of liver cirrhosis.
Methods
Ethics Statement
Written consent was obtained from all participants in the
Thailand case-referent study and this study was approved by the
Institutional Review Boards of the Thailand National Cancer
Institute and the International Agency for Research on Cancer.
Study Participants
This study has been carried out using protocols, specimens and
data from the International Liver Cancer Study (ILCS), an
international initiative that aims to contribute to intervention,
prevention, early diagnosis and control of liver cancer through the
understanding of its causes and mechanisms in different popula-
tions. ILCS Thailand is a case – referent study in which subjects
were recruited from fifty five provinces all around the country
from April 2008 to December 2009. Diagnosis of hepatocellular
carcinoma and cholangiocarcinoma was based on concordant
clinical examination and abdominal imaging. Individuals assigned
to the reference group presented no clinical evidence of liver
disease and were selected among the group of patients that came
to the Institute for their annual check-up.
Quantitation of TP53 R249S Mutation in CFDNA
Circulating free DNA was extracted from 1 mL of plasma using
QiAmp circulating nucleic acid kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol for purification of
Circulating DNA from 1 mL, 2 mL or 3 mL serum or plasma.
Purified DNA was eluted from the QiAmp Silica column with
water (2650 mL) (PCR-grade, Sigma, St Louis, MO, USA).
Quantitation of extracted DNA was performed by fluorimetry
using picogreen (Molecular Probes, Eugene, OR, USA). R249S-
mutated DNA was detected and quantified in reference to an
internal standard plasmid by SOMA as described previously
[20,22]. Plasma concentrations were expressed as copies of R249S-
mutated DNA per mL of plasma. The limit of determination for
the method was 67 copies of R249S-mutated DNA/mL plasma.
Statistical Analyses
Odds ratios (ORs), x
2 and p-values were calculated using
STATA 11.1 (College Station, Texas). Odds ratios were adjusted
for sex and age as well as for HBsAg and HCV-Ab.
Results
Characteristics of Study Population
Demographic information and hepatitis infection status of cases
of HCC without cirrhosis (HCC/no cirrhosis; n=50), HCC with
cirrhosis (HCC/cirrhosis; n=34), cholangiocarcinoma (CC;
n=36), chronic liver disease (CLD; n=56) and of the reference
group (R; n=133) are presented in Table 1. Median age was 55
years (range 42–74) for HCC/cirrhosis, 52 (33–71) for HCC/no
cirrhosis, 57 (37–72) for CC and 53 (35–72) for CLD. Of note,
38% (19/50) of HCC/no cirrhosis were under 50 years of age,
compared to 18% for HCC/cirrhosis. (p=0.045). Male to female
ratio was 4:1 for HCC/no cirrhosis, 3:1 for HCC/cirrhosis, 2:1 for
CC and 1.5:1 for CLD. Figure 1 shows the geographic distribution
of the place of residence of the cases at the time of diagnosis.
Patients originated from all around the country, but were mainly
from the North-East and the Central-South regions. HCC/
cirrhosis cases tended to cluster in the Central-South region
(mainly larger Bangkok area), as compared to HCC/no cirrhosis
(predominantly rural) and to CC (predominantly originating from
north-eastern Thailand).
HBV carriage, as assessed by detection of HBsAg, was
significantly more frequent in HCC/no cirrhosis (62%; OR:
11.7, 95%CI [5.0–21.3]); HCC/cirrhosis (50%; OR: 12.3, 95%CI
[4.4–34.3]) and CLD (52%; OR: 9.6, 95%CI [4.3–21.6]) as
compared to R (14%; Reference; p=,0.001). Of note, the
proportion of HBsAg-positive subjects in the R group was higher
than expected based on current WHO health statistics for the Thai
population [9]. Conversely, CC were less associated with HBsAg
positivity than the R group (2.8%; OR: 0.2, 95%CI [0.02–1.04]).
HCV seropositivity was confirmed in 14% of HCC/no cirrhosis
and in 32.3% of HCC/cirrhosis (X2, p=0.044). As for HBV, the
lowest proportion of HCV positive patients was observed in CC
(5.6%).
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Status n (%)
Hepatocellular carcinoma
without cirrhosis
Hepatocellular
carcinoma
with cirrhosis Cholangicarginoma
Chronic liver
disease Reference group
N 50 34 36 56 133
,40 5 (10) 0 (0) 1 (2.8) 5 (8.9) 5 (3.8)
Age, years 40–49 14 (28) 6 (17.6) 6 (16.7) 12 (21.4) 28 (21)
50–59 18 (36) 19 (55.9) 13 (36.1) 26 (46.5) 51 (38.4)
$60 13 (26) 9 (26.5) 16 (44.4) 13 (23.2) 49 (36.8)
Sex Men 41 (82) 26 (76.5) 23 (63.9) 34 (60.7) 77 (57.9)
Women 9 (18) 8 (23.5) 13 (36.1) 22 (39.3) 56 (42.1)
Negative 19 (38) 16 (47) 34 (94.4) 27 (48.2) 112 (84.2)
HBsAg Positive 31 (62) 17 (50) 1 (2.8) 29 (51.8) 19 (14.3)
N/A 0 (0) 1 (3) 1 (2.8) 0 (0) 2 (1.5)
OR [95% CI]
1 11.67 [4.99–21.3] 12.32 [4.43–34.27] 0.18 [0.02–1.04] 9.64 [4.31–21.57] 1.00
Hepatitis C Negative 43 (86)* 23 (67.7) 34 (94.4) 43 (76.8) 133 (100)
Positive 7 (14)* 11 (32.3) 2 (5.6) 13 (23.2) 0 (0)
1OR for HBsAg positivity calculated in relation to the R group. *X 2 test when compared HCC/no cirrhosis Vs HCC/cirrhosis (p value=0.044).
doi:10.1371/journal.pone.0037707.t001
Figure 1. Geographic distribution of liver cancer cases. Dots represent the distribution by province. Pie charts describe the distribution of
HCC/no cirrhosis (lines), HCC/cirrhosis (full black) and CC (small dots) among the Northwest, Northeast and Central-south parts of the country.
doi:10.1371/journal.pone.0037707.g001
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Figure 2 shows the proportions of subjects for each study group
with detectable R249S-mutated DNA at 6 cutoff concentrations
from 67 to 160 copies/mL plasma). At the method’s limit of
determination (67 copies/mL), the 4 liver disease groups had
similar proportions of patients positive for R249S-mutated DNA
(53–64%), clearly separated from the R group, for which only 19%
of subjects were positive. Increasing the cutoff concentration better
resolved the 5 study groups. We thus selected a lower cutoff
concentration of 150 copies/mL for further comparisons of
R249S-mutated DNA concentrations between the 4 liver disease
groups and the reference group (Figure 3).
Median plasma concentrations of R249S-mutated DNA were
higher for the HCC/no cirrhosis group (328 copies/mL) than
HCC/cirrhosis group (273 copies/mL) with wide concentration
ranges for both groups (154–11,576 copies/mL and 152–8,675
copies/mL, respectively). Of note, although the medians for the
two HCC groups are similar, the number of individuals in the
70% percentile is higher for HCC/no cirrhosis (n=11) than for
HCC/cirrhosis (n=3).In contrast, for the CC, CLD and R
groups, median plasma concentrations of R249S-mutated DNA
were lower (252, 256 and 20 copies/mL), respectively, and
concentration ranges smaller ([170–446], [150–352] and [155–
216]). Taken together, data in Figures 2 and 3 show that (1) high
copy numbers of R249S were associated with HCC (with or
without cirrhosis), whereas CC, CLD and R groups had similarly
low R249S copy numbers; (2) the proportion of patients with
measurable plasma concentrations of R249S-mutated DNA was
highest in the HCC/no cirrhosis group (44%). Strikingly, this
proportion was lower for the HCC/cirrhosis (21%) and CC (22%)
groups, which were both higher than CLD (12%) and R (3%)
groups. These results indicate that plasma concentrations of
R249S-mutated DNA occurred most often and at highest
concentrations in the HCC/no cirrhosis group, although measur-
able lower concentrations were observed in the other disease
groups.
Association between Plasma R249S-mutated DNA,
Chronic Hepatitis Virus Infection and Alpha-fetoprotein
Levels
We next examined associations between plasma R249S-mutated
DNA positivity (.150 copies/mL) and markers of chronic HBV
and HCV infections (Table 2) and levels of alpha-fetoprotein
(AFP) (Table 3). Table 2 shows that HCC with or without cirrhosis
was strongly associated with HBsAg positivity in patients with both
high and low plasma concentrations of R249S-mutated DNA.
However, the strongest association was observed in patients with
HCC/no cirrhosis and high plasma concentrations of R249S-
mutated DNA. In the latter group, the proportion of HBsAg-
positive patients (73%) was higher than in patients with HCC/
cirrhosis at either high or low plasma concentrations of R249S-
mutated DNA (43% and 52%, respectively) or patients with
HCC/no cirrhosis with low plasma concentrations of R249S-
mutated DNA (54%). With HCV, a significant association was
observed between HCV infection and HCC/cirrhosis, irrespective
of plasma concentration of R249S-mutated DNA (p=0.03). Of
note, only HCC/cirrhosis was significantly associated with HCV
infection when compared to non-HCC subjects (CC, CLD and
reference group) (Table 2). Table 3 shows that the distribution of
patients with levels of AFP.100 ng/mL was similar between
HCC/no cirrhosis and HCC/cirrhosis. However, in the latter
group, there was a larger proportion of patients with undetectable
or low levels of AFP among HCC/cirrhosis with low plasma
concentrations of R249S-mutated DNA (56% vs 0%, p=0.025).
Discussion
In this study, we have used a highly sensitive and quantitative
mass spectrometric method, SOMA, to investigate the relation-
Figure 2. Distribution of the liver disease and reference groups at different cutoffs of positivity of TP53 R249S mutation. At 150
copies/mL there is a clear distinction among the three liver cancer groups the chronic liver disease subjects and the reference group. The proportion
of patients at this cut-off is higher in HCC/no cirrhosis (44%) than in all other groups (HCC/cirrhosis (21%), CC (22%), CLD (12%) and R (3)).
doi:10.1371/journal.pone.0037707.g002
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R249S-mutated DNA concentrations in free circulating DNA
using blood specimens collected in a hospital case: control design.
We show that plasma R249S-mutated DNA was detected at .67
copies/mL in over 53% of patients with liver cancer or chronic
liver disease, and only in 19% of control subjects (including 8% of
HBsAg positive subjects). However, when considering only
subjects with R249S-mutated DNA concentrations .150 copies/
mL, a clear distinction could be made between the different liver
disease statuses. While 44% of HCC/no cirrhosis patients had
plasma R249S-mutated DNA concentrations greater than 150
copies/mL, this proportion dropped to 21% in patients with
HCC/cirrhosis, 22% in CC patients, 12% in CLD patients and
3% in the reference group. This observation indicates that R249S-
mutated DNA plasma concentrations greater than 150 copies/mL
are associated with HCC preferentially developing without
Figure 3. Box and whisker distributions of TP53 R249S-mutated DNA plasma concentrations ($150 copies/mL) for the different groups.
Boxes extend from 25
th to 75
th percentiles and are divided by a solid line representing the median of each centre. The median levels for the different
groups are: 328 in HCC/no cirrhosis, 273 in HCC/cirrhosis, 252 in CC, 256 in CLD and 202 in R.
doi:10.1371/journal.pone.0037707.g003
Table 2. Relation between Plasma R249S-mutated DNA and HBs-antigen (HBsAg) and HCV-antibody (HCV-ab).
Status n (%)
Hepatocellular carcinoma
without cirrhosis
Hepatocellular
carcinoma with
cirrhosis Cholangicarginoma
Chronic liver
disease Reference group
R249S+ 22 (44) 7 (21) 8 (22) 6 (11) 4 (3)
HBsAg+ 16 (73) *** 3 (43) * 0 1 (17) 1 (25)
HBsAg– 6 (27) 3 (43) 8 (100) 5 (83) 3 (75)
HBsAg NA 1 (14)
R249S– 28 (56) 27 (79) 28 (78) 50 (89) 129 (97)
HBsAg+ 15 (54) *** 14 (52) *** 1 (3.5) 28 (56) 18 (14)
HBsAg– 13 (46) 13 (48) 26 (93) 22 (44) 109 (84)
HBsAg NA 1 (3.5) 2 (2)
R249S+ 22 (44) 7 (21) 8 (22) 6 (11) 4 (3)
HCV+ 3 (14)
ns 4 (57) * 1 (13) 1 (1.8) 0
HCV– 19 (86) 3 (43) 7 (87) 5 (8.9) 4 (100)
R249S– 28 (56) 27 (79) 28 (78) 50 (89) 129 (97)
HCV+ 4 (14)
ns 7 (26) *** 1 (2.8) 12 (24) 0
HCV– 24 (86) 20 (74) 27 (75) 38 (76) 129 (100)
X2 test when compared to cholangiocarcinoma, chronic liver disease and reference group all together (*: p value ,0.05; ***: p value ,0.001; NA: Not Available; ns: non
significant).
doi:10.1371/journal.pone.0037707.t002
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DNA plasma concentrations between HCC developing in
a context of cirrhosis and CC, a pathology that originates from
non-hepatocyte liver cells and has not been shown to be associated
with exposure to aflatoxin. Patients with HCC/no cirrhosis and
with high R249S-mutated DNA plasma concentrations tended to
be more frequently HBsAg positive (73%) than patients with
HCC/no cirrhosis with low or undetectable concentrations.
Furthermore, in patients with HCC/cirrhosis, the proportion of
HBsAg positive subjects was similar, irrespective of R249S-
mutated DNA plasma concentration. Overall, these results
highlight the preferential occurrence of R249S-mutated DNA in
the plasma of subjects developing HCC in the absence of cirrhosis
and/or in subjects who are chronic carriers of HBV.
In a previous study on HCC tissues collected at the NCI,
Bangkok, we have detected plasma R249S-mutated DNA in 7/26
HCC cases (27%) [15]. Although case: control studies conducted
in the early nineties employing biomarkers of aflatoxin exposure
have concluded that levels of aflatoxin exposure were low in the
Thai population [16], a recent assessment of aflatoxin contami-
nation in two dietary staples in Thailand, peanuts and maize, has
reported mean aflatoxin levels which are 3 to 5 times higher than
the Thailand regulation limit (20 mg/kg) [23]. Thus levels of
dietary exposure to aflatoxin are far from negligible in Thailand
and the presence of the mutated DNA in plasma is consistent with
the notion that this toxin, together with HBV chronic carriage,
remains a major etiological factor for HCC in Thailand. The
apparent discrepancy between our detection of plasma R249S-
mutated DNA and the low levels of aflatoxin biomarkers detected
by case: control study in a similar population may be due to the
fact that such biomarkers are short-lived in comparison with TP53
R249S mutation in liver cells. Thus, in controls, the exposure
biomarker is present in only a small proportion of the subjects,
whereas in cases, the biomarker is no longer detectable as exposure
leading to mutation might have taken place months or years ahead
of diagnosis.
In a study on asymptomatic chronic HBV carriers in The
Gambia, West Africa, we have found that R249S-mutated DNA
could be detected at relatively low levels in the plasma of subjects
with dietary exposure to aflatoxin, with a seasonal variation that
may reflect the dynamics of exposure, mutation formation,
elimination of mutated cells and shedding of cell debris into the
bloodstream [20]. In the present study, we show that low plasma
levels of R249S-mutated DNA (.67 copies/mL plasma, compat-
ible with the lower detection limit in asymptomatic subjects from
the Gambia) are detectable in a variable proportion of controls, of
subjects with chronic liver disease and of liver cancer patients,
independently of liver cancer histological type and pathological
profile. This low concentration of R249S-mutated DNA may occur
as the consequence of ongoing exposure to aflatoxin (in controls)
and of ongoing destruction of non-cancer cells having acquired
a mutation (in patients with CLD, CC, HCC/cirrhosis or HCC/
no cirrhosis). However, when only plasma concentrations above
a higher cutoff are considered (.150 copies/mL), plasma R249S-
mutated DNA may essentially, but not exclusively occur as the
result of shedding of cellular material by cancer cells containing
the mutation. Thus, the high proportion (44%) of patients with
HCC/no cirrhosis that are positive above this level may
correspond to patients who actually have a liver tumour that
contains the mutation. In patients with HCC/cirrhosis or with
CC, the proportion of positive subjects above the 150 copies/mL
threshold is similar (21 to 22%) but the actual copy numbers are
much higher in HCC/cirrhosis patients (up to 8,675 copies/mL)
than in CC patients (up to 446 copies/mL) (Figure 3). In patients
with CC or CLD, plasma R249S-mutated DNA concentrations are
actually very low and similar to those observed in the reference
group. In the latter group, presence of R249S at levels $150
copies/mL may correspond to patients with particularly high,
ongoing levels of exposure to aflatoxin or who harbor small
populations of cells having acquired the mutation. Of the 5 control
subjects with plasma R249S-mutated DNA concentrations $150
copies/mL, only one was positive for HBsAg, indicating that
positivity for plasma R249S-mutated DNA in control subjects was
not restricted to HBV chronic carriers.
In conclusion, the present study provides evidence that
acquisition and persistence of the TP53 mutation R249S occurs
preferentially in HCC that develops in a context of chronic
infection by HBV and without clear clinical evidence of prior or
concomitant liver cirrhosis. Although pre-existing cirrhosis is
detected in the vast majority (90%) of HCC cases in Western
Europe and in the US, it is actually a less frequent phenomenon in
HCC occurring in a context of high HBV endemicity/high
exposure to aflatoxin although its exact rate of occurrence is
poorly documented. In The Gambia, we have observed that
cirrhosis was detectable in 62% of patients at the time of HCC
diagnosis and this proportion was 59% in patients with plasma
Table 3. Relation between Plasma R249S-mutated DNA and AFP.
Status n(%)
Hepatocellular carcinoma
without cirrhosis
Hepatocellular carcinoma
with cirrhosis Cholangicarginoma
Chronic liver
disease Reference group
R249S+ 22 (44) 7 (21) 8 (22) 6 (11) 4 (3)
AFP,100 7 (32) 0 7 (87) 6 (100) 4 (100)
AFP.=100 3 (14) 1 (14) 1 (13) 0 0
AFP.=400 12 (54) 6 (86) 0 0 0
R249S - 28 (56) 27 (79) 28 (78) 50 (89) 129 (97)
AFP,100 9 (32) 15 (56) 28 (100) 48 (96) 129 (100)
AFP.=100 3 (11) 3 (11) 0 2 (4) 0
AFP.=400 16 (57) 9 (33) 0 0 0
X2 test (p value)* 0.950 0.025*
*X2 test comparing individuals with R249S .=150 copies/mL against individuals with R249S ,150 copies/mL.
doi:10.1371/journal.pone.0037707.t003
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of a group of 1810 males HBV carriers aged over 30 over 7 years
led to the detection of 36 cases of HCC, 18 (50%) of which
developed without any prior evidence of cirrhosis (P.Srivatanakul,
unpublished observations). Overall, our results suggest that the
development of HCC without pre-existing cirrhosis is enhanced or
accelerated in a context of HBV chronic infection and of aflatoxin-
induced TP53 R249S mutation, suggesting that these two factors
cooperate in a distinct pathway of development of hepatocellular
carcinoma.
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